Literature DB >> 23906300

Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.

A Bolcekova, M Nemethova, A Zatkova, K Hlinkova, S Pozgayova, A Hlavata, L Kadasi, D Durovcikova, A Gerinec, K Husakova, Z Pavlovicova, M Holobrada, L Kovacs, D Ilencikova.   

Abstract

Optic pathway gliomas (OPG) occur in 15% of patients with neurofibromatosis type 1 (NF1; OMIM 162200). Genotype-phenotype correlations in patients with NF1 may help to determine the risk group for developing complications such as OPG in coincidence with other NF1.features. We evaluated 52 patients with NF1 (25 with OPG and 27 without OPG). All subjects underwent a clinical examination focused on neurofibromatosis type 1 and molecular diagnostics of NF1 gene using protocol based on RNA analysis confirming the diagnosis of NF1. In the group with OPG patients, there was a significantly higher incidence of freckling (P=0.017), neurofibromatosis bright objects (NBO) (P=0.0038), compared to the group without OPG. The differences between the groups with respect to Lisch nodules were on the borderline of statistical significance (P=0.088). The frequency of neurofibromas in the group with OPG was not significant (P=0.9). From all patients with the mutation localized in the first tertile of the NF1 gene majority (71%) had optic glioma compared to individuals who didn't have the OPG 29% (P=0.0049). Our results present the clustering of mutations in the 5'tertile of NF1 gene in patients with optic nerve glioma and suggest higher incidence of freckling and neurofibromatosis brain objects in these patients. Molecular analysis of NF1 gene is important part in complex management of NF1 patients and contributes to a better understanding of clinical picture of NF1 patients. .

Entities:  

Mesh:

Year:  2013        PMID: 23906300     DOI: 10.4149/neo_2013_084

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  19 in total

1.  NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

Authors:  Joseph A Toonen; Corina Anastasaki; Laura J Smithson; Scott M Gianino; Kairong Li; Robert A Kesterson; David H Gutmann
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

2.  Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1.

Authors:  Kimberly J Johnson; Nancy L Zoellner; David H Gutmann
Journal:  Cancer Epidemiol       Date:  2016-03-25       Impact factor: 2.984

3.  Exploring the genetic basis for clinical variation in neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Expert Rev Neurother       Date:  2016-05-30       Impact factor: 4.618

4.  No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.

Authors:  Sonja Hutter; Rosario M Piro; Sebastian M Waszak; Hildegard Kehrer-Sawatzki; Reinhard E Friedrich; Alvaro Lassaletta; Olaf Witt; Jan O Korbel; Peter Lichter; Martin U Schuhmann; Stefan M Pfister; Uri Tabori; Victor F Mautner; David T W Jones
Journal:  Hum Genet       Date:  2016-03-11       Impact factor: 4.132

5.  Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1.

Authors:  Salmafatima S Abadin; Nancy L Zoellner; Melody Schaeffer; Bree Porcelli; David H Gutmann; Kimberly J Johnson
Journal:  J Pediatr       Date:  2015-05-28       Impact factor: 4.406

Review 6.  Germline genetic landscape of pediatric central nervous system tumors.

Authors:  Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

7.  Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma.

Authors:  Nicole M Brossier; Sharanya Thondapu; Olivia M Cobb; Sonika Dahiya; David H Gutmann
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 8.  Optic Pathway Gliomas in Neurofibromatosis Type 1.

Authors:  Cynthia J Campen; David H Gutmann
Journal:  J Child Neurol       Date:  2018-01       Impact factor: 1.987

Review 9.  Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

10.  Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1.

Authors:  Bree Porcelli; Nancy L Zoellner; Salmafatima S Abadin; David H Gutmann; Kimberly J Johnson
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.